Phio Pharmaceuticals Corp. (NASDAQ: PHIO)

Phio Pharmaceuticals Corp., known by its ticker symbol PHIO, is a clinical-stage biotechnology company operating in the immuno-oncology sector. The organization is dedicated to the discovery and development of innovative cancer treatments, with a focus on creating new pathways towards a cancer-free future.

Phio Pharmaceuticals Corp. primarily generates revenue through the development of immuno-oncology therapeutics harnessing its unique INTASYL self-delivering RNAi technology platform. This platform enables the creation of INTASYL compounds, which are sequences of chemically modified nucleotides designed to silence genes that tumors employ to evade the immune system. The company's main products include PH-762 and PH-894, which target specific proteins that diminish the body's capacity to combat cancer. The company's customer base comprises patients with various types of cancer, such as skin cancer, melanoma, and Merkel cell carcinoma.

The INTASYL platform serves as a foundation for the development of specific patented compounds. PH-762 is one such compound, intended to reduce the expression of cell death protein 1 (PD-1). Preclinical studies have demonstrated potent anti-tumoral effects and a dose-dependent inhibition of tumor growth in PD-1 responsive and refractory models. PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial for the treatment of patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Another prominent product is PH-894, an INTASYL compound that silences BRD4, a protein that controls gene expression in both T cells and tumor cells. Preclinical studies have shown a strong, concentration-dependent, and durable silencing of BRD4 in T cells and various cancer cells. PH-894 can be easily incorporated into current ACT manufacturing processes and has demonstrated preclinical efficacy in ACT applications.

Phio Pharmaceuticals Corp. has identified synergies between INTASYL compounds and other therapies. Preclinical studies have demonstrated enhanced potency in vivo when INTASYL compounds are combined with antibodies. This combination may also increase the number of addressable drug targets. Unlike other antibody combination approaches, INTASYL can target multiple protein drug targets in a specific therapeutic dose, enhancing potency while maintaining a favorable tolerability and safety profile.

Phio Pharmaceuticals Corp. boasts a robust intellectual property portfolio, with 81 issued patents and 40 pending patent applications covering its INTASYL platform and compounds. The company has also secured key intellectual property license agreements, including an agreement with Advanced RNA Technologies, LLC, which granted Phio Pharmaceuticals Corp. its existing patent and technology rights related to the INTASYL technology.

Operating within the immuno-oncology field, Phio Pharmaceuticals Corp. is subject to stringent government regulations, such as those imposed by the U.S. Food and Drug Administration (FDA). Compliance with these regulations is crucial, as failure to do so could result in administrative or judicial enforcement actions, including refusal to permit clinical trials, refusal to approve applications, issuance of warning letters, product recalls, fines, and restitution, disgorgement, or civil or criminal penalties.